

Panel on Health Services

Subcommittee on Issues Relating to the Support for Cancer Patients

**List of follow-up actions required of the Administration
arising from the discussion at the meeting on 16 December 2019**

The Administration was requested to:

- (a) provide for members' reference a general comparison of the pricing of cancer drugs among Hong Kong, the Mainland and Taiwan, and account for the discrepancies, if any;
- (b) consider the suggestion of setting up a mechanism to join hands with the Greater Bay Area or the whole Mainland in procurement of cancer drugs with a view to lowering Hong Kong's cancer drug costs through bulk purchase;
- (c) advise whether and, if so, how the Administration and the Hospital Authority would further streamline the process for listing of new cancer drugs on the Hospital Authority Drug Formulary and introduction of self-financed cancer drugs into the safety net; and
- (d) provide a consolidated written response to the views expressed by deputations at the meeting and in the written submissions.